Application of chimeric mice with humanized liver for study of human-specific drug metabolism

Drug Metabolism and Disposition

Volumn 42, Issue 6, 2014, Pages 1055-1065

  Bateman, Thomas J ^a   Reddy, Vijay G B ^a   Kakuni, Masakazu ^b   Morikawa, Yoshio ^b   Kumar, Sanjeev ^a,c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b PhoenixBio USA Corporation   (Japan)

^c VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; DRUG; DRUG METABOLIZING ENZYME; LAMOTRIGINE; MRK A; PROPAFENONE; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL CELL; ARTICLE; CHIMERA; CHIMERIC MOUSE; CONTROLLED STUDY; DRUG EXCRETION; DRUG METABOLISM; GLUCURONIDATION; HUMAN; HUMAN CELL; LIVER METABOLISM; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; OXIDATION; PRIORITY JOURNAL; SCID MOUSE; XENOBIOTIC METABOLISM; ANIMAL; DRUG EFFECTS; GENETICS; LIVER; LIVER CELL; METABOLIC CLEARANCE RATE; METABOLISM; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; CHIMERA; HEPATOCYTES; HUMANS; LIVER; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, SCID; MICE, TRANSGENIC; PHARMACEUTICAL PREPARATIONS;

EID: 84901011638     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.056978     Document Type: Article

References (44)

1. Anderson S, Luffer-Atlas D, and Knadler MP (2009) Predicting circulating human metabolites: how good are we? Chem Res Toxicol 22:243-256.
2. Argikar UA, Senekeo-Effenberger K, Larson EE, Tukey RH, and Remmel RP (2009) Studies on induction of lamotrigine metabolism in transgenic UGT1 mice. Xenobiotica 39: 826-835.
3. Azuma H, Paulk N, Ranade A, Dorrell C, Al-Dhalimy M, Ellis E, Strom S, Kay MA, Finegold M, and Grompe M (2007) Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol 25:903-910.
4. Biton V (2006) Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. Expert Opin Drug Metab Toxicol 2:1009-1018.
5. Botsch S, Gautier J-C, Beaune P, Eichelbaum M, and Kroemer HK (1993) Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol 43:120-126.
6. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, and Peck AW (1987) Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 42:535-541.
7. Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, Nedderman A, Goulet L, Smith E, and Bu HZ, et al. (2009) Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22:357-368.
8. De Serres M, Bowers G, Boyle G, Beaumont C, Castellino S, Sigafoos J, Dave M, Roberts A, Shah V, and Olson K, et al. (2011) Evaluation of a chimeric (uPA+/+)/SCID mouse model with a humanized liver for prediction of human metabolism. Xenobiotica 41:464-475.
9. Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, and Eichelbaum M (1999) Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. Pharmacogenetics 9:551-559.
10. Doig MV and Clare RA (1991) Use of thermospray liquid chromatography-mass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, Lamotrigine. J Chromatogr A 554:181-189.
11. Emoto C, Yamato Y, Sato Y, Ohshita H, Katoh M, Tateno C, Yokoi T, Yoshizato K, and Iwasaki K (2008) Non-invasive method to detect induction of CYP3A4 in chimeric mice with a humanized liver. Xenobiotica 38:239-248.
12. Foster JR, Lund G, Sapelnikova S, Tyrrell DL, and Kneteman NM (2014) Chimeric rodents with humanized liver: bridging the preclinical/clinical trial gap in ADME/toxicity studies. Xenobiotica 44:109-122.
13. Green MD, Bishop WP, and Tephly TR (1995) Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides. Drug Metab Dispos 23:299-302.
14. Green MD and Tephly TR (1998) Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins. Drug Metab Dispos 26:860-867.
15. Hawes EM (1998) N+-glucuronidation, a common pathway in human metabolism of drugs with a tertiary amine group. Drug Metab Dispos 26:830-837.
16. Hege HG, Hollmann M, Kaumeier S, and Lietz H (1984) The metabolic fate of 2H-labelled propafenone in man. Eur J Drug Metab Pharmacokinet 9:41-55.
17. Inoue T, Nitta K, Sugihara K, Horie T, Kitamura S, and Ohta S (2008) CYP2C9-catalyzed metabolism of S-warfarin to 7-hydroxywarfarin in vivo and in vitro in chimeric mice with humanized liver. Drug Metab Dispos 36:2429-2433.
18. Inoue T, Sugihara K, Ohshita H, Horie T, Kitamura S, and Ohta S (2009) Prediction of human disposition toward S-3H-warfarin using chimeric mice with humanized liver. Drug Metab Pharmacokinet 24:153-160.
19. Katoh M, Matsui T, Nakajima M, Tateno C, Kataoka M, Soeno Y, Horie T, Iwasaki K, Yoshizato K, and Yokoi T (2004) Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab Dispos 32:1402-1410.
20. Katoh M, Matsui T, Nakajima M, Tateno C, Soeno Y, Horie T, Iwasaki K, Yoshizato K, and Yokoi T (2005a) In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver. Drug Metab Dispos 33:754-763.
21. Katoh M, Matsui T, Okumura H, Nakajima M, Nishimura M, Naito S, Tateno C, Yoshizato K, and Yokoi T (2005b) Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab Dispos 33:1333-1340.
22. Katoh M, Sawada T, Soeno Y, Nakajima M, Tateno C, Yoshizato K, and Yokoi T (2007) In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. J Pharm Sci 96:428-437.
23. Katoh M, Watanabe M, Tabata T, Sato Y, Nakajima M, Nishimura M, Naito S, Tateno C, Iwasaki K, and Yoshizato K, et al. (2005c) In vivo induction of human cytochrome P450 3A4 by rifabutin in chimeric mice with humanized liver. Xenobiotica 35:863-875.
24. King C, Tang W, Ngui J, Tephly T, and Braun M (2001) Characterization of rat and human UDPglucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 61:49-53.
25. Kumar S, Samuel K, Subramanian R, Braun MP, Stearns RA, Chiu SH, Evans DC, and Baillie TA (2002) Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide. J Pharmacol Exp Ther 303:969-978.
26. Lagas JS, Sparidans RW, Wagenaar E, Beijnen JH, and Schinkel AH (2010) Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATPbinding cassette efflux transporters. Mol Pharmacol 77:687-694.
27. Luo H, Hawes EM, McKay G, Korchinski ED, and Midha KK (1995) N(+)-glucuronidation of aliphatic tertiary amines in human: antidepressant versus antipsychotic drugs. Xenobiotica 25: 291-301.
28. Maggs JL, Naisbitt DJ, Tettey JN, Pirmohamed M, and Park BK (2000) Metabolism of lamotrigine to a reactive arene oxide intermediate. Chem Res Toxicol 13:1075-1081.
29. Nishimura M, Yoshitsugu H, Yokoi T, Tateno C, Kataoka M, Horie T, Yoshizato K, and Naito S (2005) Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver. Xenobiotica 35:877-890.
30. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
31. Ogura K, Ishikawa Y, Kaku T, Nishiyama T, Ohnuma T, Muro K, and Hiratsuka A (2006) Quaternary ammonium-linked glucuronidation of trans-4- hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem Pharmacol 71:1358-1369.
32. Parsons DN and Miles DW (1984) Metabolic studies with BW430C, a novel anticonvulsant. Proceedings of the Annual Meeting of the American Epilepsy Society, 1984, San Francisco, CA. Epilepsia 25:656 (Abstract).
33. Remmel RP and Sinz MW (1991) A quaternary ammonium glucuronide is the major metabolite of lamotrigine in guinea pigs. In vitro and in vivo studies. Drug Metab Dispos 19:630-636.
34. Riess W, Stierlin H, Degen P, Faigle JW, G?rardin A, Moppert J, Sallmann A, Schmid K, Schweizer A, and Sulc M, et al. (1978) Pharmacokinetics and metabolism of the antiinflammatory agent Voltaren. Scand J Rheumatol Suppl 22:17-29.
35. Sanoh S, Horiguchi A, Sugihara K, Kotake Y, Tayama Y, Uramaru N, Ohshita H, Tateno C, Horie T, and Kitamura S, et al. (2012) Predictability of metabolism of ibuprofen and naproxen using chimeric mice with human hepatocytes. Drug Metab Dispos 40:2267-2272.
36. Seitz S, Kretz-Rommel A, Oude Elferink RP, and Boelsterli UA (1998) Selective protein adduct formation of diclofenac glucuronide is critically dependent on the rat canalicular conjugate export pump (Mrp2). Chem Res Toxicol 11:513-519.
37. Stierlin H and Faigle JW (1979) Biotransformation of diclofenac sodium (Voltaren) in animals and in man. II. Quantitative determination of the unchanged drug and principal phenolic metabolites, in urine and bile. Xenobiotica 9:611-621.
38. Stierlin H, Faigle JW, Sallmann A, Küng W, Richter WJ, Kriemler HP, Alt KO, and Winkler T (1979) Biotransformation of diclofenac sodium (Voltaren) in animals and in man. I. Isolation and identification of principal metabolites. Xenobiotica 9:601-610.
39. Strom SC, Davila J, and Grompe M (2010) Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity. Methods Mol Biol 640:491-509.
40. Suemizu H, Hasegawa M, Kawai K, Taniguchi K, Monnai M, Wakui M, Suematsu M, Ito M, Peltz G, and Nakamura M (2008) Establishment of a humanized model of liver using NOD/ Shi-scid IL2Rgnull mice. Biochem Biophys Res Commun 377:248-252.
41. Tan W, Li Q, McKay G, and Semple HA (1998) Identification and determination of phase I metabolites of propafenone in rat liver perfusate. J Pharm Biomed Anal 16:991-1003.
42. Tanoue C, Sugihara K, Uramaru N, Tayama Y, Watanabe Y, Horie T, Ohta S, and Kitamura S (2013) Prediction of human metabolism of the sedative-hypnotic zaleplon using chimeric mice transplanted with human hepatocytes. Xenobiotica 43:956-962.
43. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, and Hino H, et al. (2004) Near completely humanized liver in mice shows humantype metabolic responses to drugs. Am J Pathol 165:901-912.
44. Zhou SF, Zhou ZW, Yang LP, and Cai JP (2009) Substrates, inducers, inhibitors and structureactivity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem 16:3480-3675.